



DexTech

Know-how in Translational Research

Press release 2022-10-28

DexTech Medical AB, 556664-6203

Bulletin from the Annual General Meeting

Today, 28 October 2022, the Annual General Meeting of DexTech Medical AB was held. All decisions were taken by the required majority.

Resolution on adoption of the income statement and balance sheet

The AGM resolved to adopt the presented income statement and balance sheet.

Resolution on appropriation of the company's earnings in accordance with the adopted balance sheet

The AGM resolved to dispose of the company's earnings in accordance with the Board's proposal, and that no dividends be paid for the financial year 2021/2022.

Resolution on discharge from liability for the members of the Board of Directors and the CEO

The AGM resolved to discharge the members of the Board of Directors and the CEO from liability.

Determination of the number of board members and deputy board members

The AGM resolved that the number of board members shall be five members and that no deputies shall be elected.

Election of board of directors and auditor

The AGM resolved to re-elect Andreas Segerros, Per-Olov Asplund, Rolf Eriksson and Svante Wadman and Peter Benson was newly elected. At the following statutory board meeting, Andreas Segerros was re-elected chairman of the board. KPMG AB, with Per Hammar as auditor in charge, was re-elected as auditor for the period until the end of the next Annual General Meeting.

Determination of fees to the Board of Directors and the auditors

It was resolved that SEK 400,000 in fees shall be paid to the Board of Directors for the period until the end of the next Annual General Meeting. It was decided that board fees are distributed so that SEK 200,000 will be paid to Andreas Segerros and SEK 200,000 to Peter Benson. It was decided that fees to the auditor shall be paid in amounts according to approved invoices.

Decision on incentive program

It was decided to approve the presented proposal for an incentive program. It was noted that the subscription price was set at SEK 0.13 and that the resolution was adopted by all shareholders present.

For more information, contact

Gösta Lundgren - CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-post: gosta.lundgren@dextechmedical.com

The information was submitted for publication, through the agency of the contact person set out above, on 28 October 2022.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate no later than after the completed phase II study. DexTech Medical AB is listed on Spotlight Stock Market.